Selecting Between the Currently Available CAR-T Therapies for R/R MM: Patient Considerations and Criteria

Opinion
Video

Panelists discuss how patient selection criteria for second-line chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma encompass both clinical eligibility guidelines and practical considerations, including geographical and financial factors.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Which patients do you think about for chimeric antigen receptor (CAR) T-cell therapy in second-line treatment for relapsed/refractory multiple myeloma (ciltacabtagene autoleucel vs idecabtagene vicleucel)?
      • Can you describe the specific criteria/institutional guidelines used to determine patient eligibility for CAR T-cell therapy referral?
      • How do nonmedical factors (location, money, etc) affect patient selection?
      Related Content